Victory Capital Management Inc. Decreases Stock Holdings in Gilead Sciences, Inc. $GILD

Victory Capital Management Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 2,731,286 shares of the biopharmaceutical company’s stock after selling 109,808 shares during the period. Victory Capital Management Inc.’s holdings in Gilead Sciences were worth $335,238,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ares Financial Consulting LLC purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $28,000. Financial Consulate Inc. raised its position in shares of Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. raised its position in shares of Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 86 shares during the last quarter. BOCHK Asset Management Ltd purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $31,000. Finally, Swiss RE Ltd. purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $31,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. The trade was a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 68,000 shares of company stock worth $9,047,570. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $125.59 on Friday. The company’s fifty day moving average price is $133.16 and its 200 day moving average price is $134.28. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29. The stock has a market capitalization of $155.93 billion, a P/E ratio of 17.11 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter last year, the company earned $1.81 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be issued a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive topline Phase 3 results for their once-weekly oral HIV regimen, a potentially important catalyst for Gilead’s HIV franchise and long-term growth. Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
• Positive Sentiment: Bernstein reiterated a Buy view on Gilead, and unusual call option activity suggests traders are positioning for upside ahead of additional catalysts. Gilead Sciences (GILD) Gets a Buy from Bernstein
• Positive Sentiment: The company advanced a Phase 2 study of denikitug in difficult-to-treat colorectal cancer, adding another pipeline readout that could broaden Gilead’s oncology prospects. Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
• Positive Sentiment: Gilead is donating remdesivir to Uganda to support Ebola response efforts, reinforcing the company’s reputation in infectious disease care and public-health leadership. Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
• Neutral Sentiment: Gilead and the Gilead Foundation announced about $3 million in funding with the National AIDS Memorial for HIV/AIDS education and leadership initiatives, a brand-building effort with limited near-term earnings impact. National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
• Neutral Sentiment: Erste Group slightly lowered its FY2026 earnings estimate for Gilead, but the revision was small and stays close to the broader loss expectations already in place. Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
• Negative Sentiment: Recent commentary suggests Gilead’s stock has pulled back from its 50-day and 200-day moving averages, indicating some short-term technical pressure despite the positive pipeline news.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Daiwa Securities Group cut their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a report on Monday, February 23rd. Morgan Stanley cut their price target on shares of Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Leerink Partners cut their price target on shares of Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Finally, Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.